GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Earnings Yield (Joel Greenblatt) %

10x Genomics (10x Genomics) Earnings Yield (Joel Greenblatt) %

: -3.90% (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

10x Genomics's Enterprise Value for the quarter that ended in Dec. 2023 was $6,371.2 Mil. 10x Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-248.7 Mil. 10x Genomics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -3.90%.

The historical rank and industry rank for 10x Genomics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

TXG' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9.29   Med: -2.78   Max: -0.3
Current: -7.89

During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of 10x Genomics was -0.30%. The lowest was -9.29%. And the median was -2.78%.

TXG's Earnings Yield (Joel Greenblatt) % is ranked worse than
75.52% of 674 companies
in the Healthcare Providers & Services industry
Industry Median: 2.59 vs TXG: -7.89

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. 10x Genomics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


10x Genomics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for 10x Genomics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only -0.40 -3.61 -0.33 -4.18 -3.90

10x Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.18 -2.75 -2.66 -4.73 -3.90

Competitive Comparison

For the Health Information Services subindustry, 10x Genomics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics Earnings Yield (Joel Greenblatt) % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Earnings Yield (Joel Greenblatt) % falls into.



10x Genomics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

10x Genomicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-248.73/6371.2312
=-3.90 %

10x Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-248.7 Mil.



10x Genomics  (NAS:TXG) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


10x Genomics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics (10x Genomics) Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006